These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 17572303)
1. Amplification of zinc finger gene 217 (ZNF217) and cancer: when good fingers go bad. Quinlan KG; Verger A; Yaswen P; Crossley M Biochim Biophys Acta; 2007 Jun; 1775(2):333-40. PubMed ID: 17572303 [TBL] [Abstract][Full Text] [Related]
2. Silencing of ZNF217 gene influences the biological behavior of a human ovarian cancer cell line. Sun G; Zhou J; Yin A; Ding Y; Zhong M Int J Oncol; 2008 May; 32(5):1065-71. PubMed ID: 18425333 [TBL] [Abstract][Full Text] [Related]
4. The candidate oncogene ZNF217 is frequently amplified in colon cancer. Rooney PH; Boonsong A; McFadyen MC; McLeod HL; Cassidy J; Curran S; Murray GI J Pathol; 2004 Nov; 204(3):282-8. PubMed ID: 15476264 [TBL] [Abstract][Full Text] [Related]
5. Specific recognition of ZNF217 and other zinc finger proteins at a surface groove of C-terminal binding proteins. Quinlan KG; Nardini M; Verger A; Francescato P; Yaswen P; Corda D; Bolognesi M; Crossley M Mol Cell Biol; 2006 Nov; 26(21):8159-72. PubMed ID: 16940172 [TBL] [Abstract][Full Text] [Related]
6. Chromosome 20q13.2 ZNF217 locus amplification correlates with decreased E-cadherin expression in ovarian clear cell carcinoma with PI3K-Akt pathway alterations. Huang HN; Huang WC; Lin CH; Chiang YC; Huang HY; Kuo KT Hum Pathol; 2014 Nov; 45(11):2318-25. PubMed ID: 25281027 [TBL] [Abstract][Full Text] [Related]
7. Prognostic and therapeutic impact of the chromosome 20q13.2 ZNF217 locus amplification in ovarian clear cell carcinoma. Rahman MT; Nakayama K; Rahman M; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K Cancer; 2012 Jun; 118(11):2846-57. PubMed ID: 22139760 [TBL] [Abstract][Full Text] [Related]
8. The ZNF217 gene amplified in breast cancers promotes immortalization of human mammary epithelial cells. Nonet GH; Stampfer MR; Chin K; Gray JW; Collins CC; Yaswen P Cancer Res; 2001 Feb; 61(4):1250-4. PubMed ID: 11245413 [TBL] [Abstract][Full Text] [Related]
9. [Oncogene ZNF217 amplification on chromosome 20 q in ovarian serous cystadenocarcinoma and its clinical implications]. Li J; Zhong M; Song LL; Su GD Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jun; 26(6):824-5. PubMed ID: 16793610 [TBL] [Abstract][Full Text] [Related]
10. Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. Collins C; Rommens JM; Kowbel D; Godfrey T; Tanner M; Hwang SI; Polikoff D; Nonet G; Cochran J; Myambo K; Jay KE; Froula J; Cloutier T; Kuo WL; Yaswen P; Dairkee S; Giovanola J; Hutchinson GB; Isola J; Kallioniemi OP; Palazzolo M; Martin C; Ericsson C; Pinkel D; Albertson D; Li WB; Gray JW Proc Natl Acad Sci U S A; 1998 Jul; 95(15):8703-8. PubMed ID: 9671742 [TBL] [Abstract][Full Text] [Related]
11. ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells. Krig SR; Miller JK; Frietze S; Beckett LA; Neve RM; Farnham PJ; Yaswen PI; Sweeney CA Oncogene; 2010 Oct; 29(40):5500-10. PubMed ID: 20661224 [TBL] [Abstract][Full Text] [Related]
12. Biochemical characterization of the zinc-finger protein 217 transcriptional repressor complex: identification of a ZNF217 consensus recognition sequence. Cowger JJ; Zhao Q; Isovic M; Torchia J Oncogene; 2007 May; 26(23):3378-86. PubMed ID: 17130829 [TBL] [Abstract][Full Text] [Related]
13. The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression. Littlepage LE; Adler AS; Kouros-Mehr H; Huang G; Chou J; Krig SR; Griffith OL; Korkola JE; Qu K; Lawson DA; Xue Q; Sternlicht MD; Dijkgraaf GJ; Yaswen P; Rugo HS; Sweeney CA; Collins CC; Gray JW; Chang HY; Werb Z Cancer Discov; 2012 Jul; 2(7):638-51. PubMed ID: 22728437 [TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target. Fejzo MS; Dering J; Ginther C; Anderson L; Ramos L; Walsh C; Karlan B; Slamon DJ Genes Chromosomes Cancer; 2008 Oct; 47(10):873-83. PubMed ID: 18615678 [TBL] [Abstract][Full Text] [Related]
15. [Study on amplification of ZNF217 in primary gastric carcinoma]. Zhu YQ; Zhu ZG; Liu BY; Chen XH; Zhang Y; Yin HR Zhonghua Wei Chang Wai Ke Za Zhi; 2005 Jan; 8(1):60-2. PubMed ID: 16149004 [TBL] [Abstract][Full Text] [Related]
16. Gene amplification of ZNF217 located at chr20q13.2 is associated with lymph node metastasis in ovarian clear cell carcinoma. Rahman MT; Nakayama K; Rahman M; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Nakayama N; Otsuki Y; Nakayama S; Miyazaki K Anticancer Res; 2012 Aug; 32(8):3091-5. PubMed ID: 22843878 [TBL] [Abstract][Full Text] [Related]
17. Detection of Her2/neu, c-MYC and ZNF217 gene amplification during breast cancer progression using fluorescence in situ hybridization. Shimada M; Imura J; Kozaki T; Fujimori T; Asakawa S; Shimizu N; Kawaguchi R Oncol Rep; 2005 Apr; 13(4):633-41. PubMed ID: 15756435 [TBL] [Abstract][Full Text] [Related]
18. Differentially regulated genes as putative targets of amplifications at 20q in ovarian cancers. Watanabe T; Imoto I; Katahira T; Hirasawa A; Ishiwata I; Emi M; Takayama M; Sato A; Inazawa J Jpn J Cancer Res; 2002 Oct; 93(10):1114-22. PubMed ID: 12417041 [TBL] [Abstract][Full Text] [Related]
19. Learning the local Bayesian network structure around the ZNF217 oncogene in breast tumours. Prestat E; de Morais SR; Vendrell JA; Thollet A; Gautier C; Cohen PA; Aussem A Comput Biol Med; 2013 May; 43(4):334-41. PubMed ID: 23375235 [TBL] [Abstract][Full Text] [Related]
20. The dark side of ZNF217, a key regulator of tumorigenesis with powerful biomarker value. Cohen PA; Donini CF; Nguyen NT; Lincet H; Vendrell JA Oncotarget; 2015 Dec; 6(39):41566-81. PubMed ID: 26431164 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]